Enzo Biochem Inc. (NYSE:ENZ) fell 1.2% during trading on Friday . The company traded as low as $5.87 and last traded at $5.92, with a volume of 187,143 shares traded. The stock had previously closed at $5.99.

Separately, Zacks Investment Research upgraded shares of Enzo Biochem from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th.

The company has a market cap of $274.81 million and a price-to-earnings ratio of 15.55. The company has a 50 day moving average price of $5.98 and a 200 day moving average price of $5.02.

Enzo Biochem (NYSE:ENZ) last posted its earnings results on Wednesday, June 8th. The company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.02. During the same period in the previous year, the firm earned ($0.07) earnings per share. The business had revenue of $18.16 million for the quarter, compared to the consensus estimate of $24.50 million. Equities research analysts predict that Enzo Biochem Inc. will post ($0.23) EPS for the current year.

Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.